Engineering and design of blood substitutes

Kevin E. Sanders; Gary Ackers; Stephen Sligar

doi:10.1016/S0959-440X(96)80120-5

Engineering and design of blood substitutes

Kevin E. Sanders, Gary Ackers, Stephen Sligar

Biochemistry

Research output: Contribution to journal › Article › peer-review

Abstract

Clinical experiences with chemically modified and genetically engineered hemoglobin blood substitutes have uncovered new side-effects that must be addressed before a viable oxygen-carrying alternative to blood can be developed. These include, among others, vasoactivity and rapid autoxidation resulting in free-radical-mediated toxicity. Research is now being directed towards understanding the mechanisms of these toxic side-effects and developing methods of overcoming them.

Original language	English (US)
Pages (from-to)	534-540
Number of pages	7
Journal	Current Opinion in Structural Biology
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/S0959-440X(96)80120-5
State	Published - Aug 1996

ASJC Scopus subject areas

Structural Biology
Molecular Biology

Access to Document

10.1016/S0959-440X(96)80120-5

Cite this

@article{737a9f0f687c4eef8b84aae34e2fb6d4,

title = "Engineering and design of blood substitutes",

abstract = "Clinical experiences with chemically modified and genetically engineered hemoglobin blood substitutes have uncovered new side-effects that must be addressed before a viable oxygen-carrying alternative to blood can be developed. These include, among others, vasoactivity and rapid autoxidation resulting in free-radical-mediated toxicity. Research is now being directed towards understanding the mechanisms of these toxic side-effects and developing methods of overcoming them.",

author = "Sanders, {Kevin E.} and Gary Ackers and Stephen Sligar",

year = "1996",

month = aug,

doi = "10.1016/S0959-440X(96)80120-5",

language = "English (US)",

volume = "6",

pages = "534--540",

journal = "Current Opinion in Structural Biology",

issn = "0959-440X",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Engineering and design of blood substitutes

AU - Sanders, Kevin E.

AU - Ackers, Gary

AU - Sligar, Stephen

PY - 1996/8

Y1 - 1996/8

N2 - Clinical experiences with chemically modified and genetically engineered hemoglobin blood substitutes have uncovered new side-effects that must be addressed before a viable oxygen-carrying alternative to blood can be developed. These include, among others, vasoactivity and rapid autoxidation resulting in free-radical-mediated toxicity. Research is now being directed towards understanding the mechanisms of these toxic side-effects and developing methods of overcoming them.

AB - Clinical experiences with chemically modified and genetically engineered hemoglobin blood substitutes have uncovered new side-effects that must be addressed before a viable oxygen-carrying alternative to blood can be developed. These include, among others, vasoactivity and rapid autoxidation resulting in free-radical-mediated toxicity. Research is now being directed towards understanding the mechanisms of these toxic side-effects and developing methods of overcoming them.

UR - http://www.scopus.com/inward/record.url?scp=0030220256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030220256&partnerID=8YFLogxK

U2 - 10.1016/S0959-440X(96)80120-5

DO - 10.1016/S0959-440X(96)80120-5

M3 - Article

C2 - 8794165

AN - SCOPUS:0030220256

VL - 6

SP - 534

EP - 540

JO - Current Opinion in Structural Biology

JF - Current Opinion in Structural Biology

SN - 0959-440X

IS - 4

ER -

Engineering and design of blood substitutes

Abstract

ASJC Scopus subject areas

Access to Document

Other links

Fingerprint

Cite this